SCHEDULE: Major Investor Reduces Tenaya Therapeutics Stake

The Column Group entities report significant sales of Tenaya Therapeutics common stock, reducing their overall exposure.

Summary

• This Amendment No. 7 updates the Schedule 13D for Tenaya Therapeutics, Inc., adding Tim Kutzkey and Peter Svennilson as Reporting Persons due to internal changes within The Column Group's management structure.
• The Column Group Opportunity III LP, along with its general partners and managing members (including Kutzkey and Svennilson), beneficially owns 49,313,559 shares of Tenaya Therapeutics common stock, representing 23.1% of the class.
• This beneficial ownership calculation is based on 213,744,535 shares of Common Stock outstanding as of December 15, 2025.
• The reported beneficial ownership excludes warrants to purchase 53,571,426 shares of Common Stock, which are not exercisable within 60 days due to beneficial ownership limitations.
• Between February 20, 2026, and February 25, 2026, TCG III LP and TCG III-A LP collectively sold an aggregate of 5,000,000 shares of Tenaya Therapeutics common stock.
• These sales occurred at weighted-average prices ranging from $0.5624 to $0.6153 per share, totaling approximately $2.89 million in aggregate sale proceeds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative development. While The Column Group retains a significant stake, the substantial sales by affiliated entities at declining prices suggest a reduction in conviction or a strategic exit from a portion of their investment, which is generally not a positive signal for the company's stock.

Negatives

• Affiliated entities of a major investor, The Column Group, sold a significant aggregate of 5,000,000 shares of common stock.
• The sales occurred at declining weighted-average prices over the reported period, from $0.6149 on February 20, 2026, to $0.5624 on February 25, 2026, indicating a downward trend in the sale price.

Risks

• Significant divestment by a major institutional investor group (The Column Group entities) could signal reduced confidence in Tenaya Therapeutics' future prospects or a strategic portfolio rebalancing.
• The sale of 5,000,000 shares over a short period may exert downward pressure on the stock price.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Tenaya Therapeutics. It primarily reports changes in beneficial ownership and recent transactions by an institutional investor group.

Industry Context

StockSavvy.ai notes that significant share sales by a venture capital group like The Column Group, especially at declining prices, can be interpreted by the market as a signal of reduced conviction in a biotechnology company's near-term prospects or a strategic shift in the investor's portfolio. This could potentially impact investor sentiment for Tenaya Therapeutics within the broader biotech sector, which often relies heavily on institutional backing and positive investor sentiment.

Comparison to Industry Standards

• The Column Group's current 23.1% stake in Tenaya Therapeutics remains substantial, indicating continued significant influence, though the recent sales by affiliated entities suggest a partial reduction in exposure.
• Compared to typical venture capital investment cycles, a partial divestment after an initial investment period is not uncommon, but the declining sale prices could be a point of concern for other investors.
• Similar situations in the biotech sector, such as when major institutional investors like Orbimed or RA Capital Management reduce stakes in their portfolio companies, often lead to increased scrutiny of the company's pipeline progress and financial health.

Stakeholder Impact

• Shareholders: The significant sales by a major institutional investor could lead to negative market sentiment and potential downward pressure on the stock price.
• Employees: No direct impact mentioned, but a decline in stock price or investor confidence could indirectly affect employee morale or stock-based compensation value.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

While a major investor has reduced its stake, The Column Group still maintains a substantial 23.1% beneficial ownership, indicating continued, albeit reduced, interest. The sales at declining prices are a negative signal, but without further information on Tenaya Therapeutics' operational performance or pipeline, a 'hold' recommendation is appropriate for investors to assess if this is a strategic rebalancing by the investor or a signal of deeper underlying issues.

Keywords

Tenaya Therapeutics, The Column Group, Schedule 13D, Beneficial Ownership, Stock Sales, Institutional Investor, Biotechnology, Venture Capital